Characterization of renal biomarkers for use in clinical trials: Effect of preanalytical processing and qualification using samples from subjects with diabetes

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 3191-3198

  Brott, David A ^a   Furlong, Stephen T ^a   Adler, Scott H ^a   Hainer, James W ^b   Arani, Ramin B ^b   Pinches, Mark ^b   Rossing, Peter ^c,d,e   Chaturvedi, Nish ^f  

^a Enabling Safety Sciences   (United States)

^b ASTRAZENECA   (United Kingdom)

^c STENO DIABETES CENTER   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Drug development; Healthy volunteers; Kidney

Indexed keywords

ALPHA 1 MICROGLOBULIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CALBINDIN; CLUSTERIN; CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; CYSTATIN C; GLUTATHIONE TRANSFERASE ALPHA; KIDNEY INJURY MARKER 1; MICROALBUMIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; TAMM HORSFALL GLYCOPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TREFOIL FACTOR 3; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACCURACY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DEMOGRAPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; RETINOPATHY; SENSITIVITY AND SPECIFICITY; URINALYSIS; ADOLESCENT; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIFFERENTIAL DIAGNOSIS; DRUG EFFECTS; KIDNEY; KIDNEY DISEASES; METABOLISM; METHODOLOGY; MIDDLE AGED; NORMAL HUMAN; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; SPECIMEN HANDLING; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; HEALTHY VOLUNTEERS; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SPECIMEN HANDLING; URINALYSIS; YOUNG ADULT;

EID: 84933074501     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S78792     Document Type: Article

References (33)

1. Guinee DG Jr, van Zee B, Houghton DC. Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy. Cancer. 1993;71(12):4050-4054.
2. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28(5):830-838.
3. Star RA. Treatment of acute renal failure. Kidney Int. 1998;54(6):1817-1831.
4. Uchino S. Creatinine. Curr Opin Crit Care. 2010;16(6):562-567.
5. Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol. 2010;28(5):455-462.
6. Harpur E, Ennulat D, Hoffman D, et al. Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat. Toxicol Sci. 2011;122(2):235-252.
7. Ozer JS, Dieterle F, Troth S, et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol. 2010;28(5):486-494.
8. Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419-431.
9. Brott DA, Adler SH, Arani R, Lovick SC, Pinches M, Furlong ST. Characterization of renal biomarkers for use in clinical trials: biomarker evaluation in healthy volunteers. Drug Des Devel Ther. 2014;8:227-237.
10. Matheis K, Laurie D, Andriamandroso C, et al. A generic operational strategy to qualify translational safety biomarkers. Drug Discov Today. 2011;16(13-14):600-608.
11. Fu WJ, Li BL, Wang SB, et al. Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration. Diabetes Res Clin Pract. 2012;95(1):105-109.
12. Fu WJ, Xiong SL, Fang YG, et al. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine. 2012;41(1):82-88.
13. Hong CY, Hughes K, Chia KS, Ng V, Ling SL. Urinary alpha1-microglobulin as a marker of nephropathy in type 2 diabetic Asian subjects in Singapore. Diabetes Care. 2003;26:338-342.
14. Matys U, Bachorzewska-Gajewska H, Malyszko J, Dobrzycki S. Assessment of kidney function in diabetic patients. Is there a role for new biomarker NGAL, cystatin C and KIM-1? Adv Med Sci. 2013;58(2):353-361.
15. Nauta FL, Boertien WE, Bakker SJ, et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care. 2011;34(4):975-981.
16. Petrica L, Petrica M, Vlad A, et al. Proximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus: a cross-sectional study. Nephron Clin Pract. 2011;118(2):c155-c164.
17. Shore N, Khurshid R, Saleem M. Alpha-1 microglobulin: a marker for early detection of tubular disorders in diabetic nephropathy. J Ayub Med Coll Abbottabad. 2010;22(4):53-55.
18. Sjølie AK, Porta M, Parving HH, Bilous R, Klein R; DIRECT Programme Study Group. The Diabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics. J Renin Angiotensin Aldosterone Syst. 2005;6(1):25-32.
19. Sjølie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trial. Lancet. 2008;372(9647):1385-1393.
20. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;3742(9647):1394-1402.
21. Bilous R, Chaturvedi N, Sjølie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes. Ann Intern Med. 2009;151(1):11-20.
22. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological). 1995;57(1):289-300.
23. Astor BC, Köttgen A, Hwang SJ, Bhavsar N, Fox CS, Coresh J. Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study. Am J Nephrol. 2011;34(4):291-297.
24. Galanti LM, Jamart J, Dell'omo J, Donckier J. Comparison of urinary excretion of albumin, alpha1-microglobulin and retinol-binding protein in diabetic patients. Diabetes Metab. 1996;22(5):324-330.
25. Kordonouri O, Jörres A, Müller C, Enders I, Gahl GM, Weber B. Quantitative assessment of urinary protein and enzyme excretion - a diagnostic programme for the detection of renal involvement in type I diabetes mellitus. Scand J Clin Lab Invest. 1992;52(8):781-790.
26. Pfleiderer S, Zimmerhackl LB, Kinne R, Manz F, Schuler G, Brandis M. Renal proximal and distal tubular function is attenuated in diabetes mellitus type 1 as determined by the renal excretion of alpha 1-microglobulin and Tamm-Horsfall protein. Clin Investig. 1993;71(12):972-977.
27. Nielsen SE, Schjoedt KJ, Astrup AS, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med. 2010;27(10):1147-1150.
28. Walton C, Bodansky HJ, Wales JK, Forbes MA, Cooper EH. Tubular dysfunction and microalbuminuria in insulin dependent diabetes. Arch Dis Child. 1988;63(3):244-249.
29. Mauer SM, Steffes MW, Brown DM. The kidney in diabetes. Am J Med. 1981;70(3):603-612.
30. Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis. 2005;12(2):177-186.
31. Hong CY, Chia KS. Markers of diabetic nephropathy. J Diabetes Complications. 1998;12(1):43-60.
32. Kordonouri O, Kahl A, Jörres A, Hopfenmüller W, Müler C, Danne T. The prevalence of incipient tubular dysfunction, but not of glomerular dysfunction, is in creased in patients with diabetes onset in childhood. J Diabetes Complications. 1999;13(5-6):320-324.
33. Yu H, Yanagisawa Y, Forbes MA, Cooper EH, Crockson RA, MacLennan IC. Alpha-1-microglobulin: an indicator protein for renal tubular function. J Clin Pathol. 1983;36:253-259.